Panelists discuss how accurate and early diagnosis remains one of the most difficult challenges in schizophrenia care. Many ...

Panelists discuss how genetic predisposition is a major determinant in schizophrenia risk, with heritability playing a ...

Panelists discuss how pharmacy-driven barriers, including delayed statin initiation and failure to escalate therapy, ...

ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to ...

Explore how the WISeR Model addresses prior authorization reform, Medicare costs, and AI's role in tackling the health care ...

Eli Lilly and Novo Nordisk will lower prices for GLP-1 receptor agonists, aligning with the Most Favored Nation executive ...

CMS introduced the GENEROUS Model to reduce Medicaid drug costs, enhance access, and improve health outcomes for ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

A new option is now approved to treat adults living with high-risk smoldering multiple myeloma. 1 The FDA has greenlit ...

In late September, oncology experts gathered in Nashville, Tennessee, for the 2025 Patient-Centered Oncology Care ® conference. Over 2 days, 15 panel discussions explored topics aligned with this year ...

Remibrutinib shows promise in treating generalized myasthenia gravis, with ongoing trials assessing its efficacy and safety for patients.

1. Willi R, Bril V, Howard J, et al. RELIEVE: a phase 3 study evaluating the efficacy and safety of remibrutinb in generalized myasthenia gravis. Presented at: American Association of Neuromuscular & ...